Art Walaszek, MD, spoke about Aduhelm and questions about its effectiveness and safety, as well as other news in the treatment and diagnosis of Alzheimer’s disease and related dementias, at the 2022 annual meeting of the American Psychiatric Association.
The diagnosis of Alzheimer’s disease relies on clinical assessment of symptoms, but blood-based biomarkers are likely coming soon and could dramatically change how the condition is diagnosed, he said.
Typical management of dementia due to Alzheimer’s involves the use of a cholinesterase inhibitor and/or memantine and the treatment of associated depression or other comorbidities. Psychosocial interventions are crucial: family and caregiver education and support, encouragement of socialization, exercise and cognitive activities, and counseling about diet.
Walaszek’s talk is featured in a July 26 news article on the website of the American Psychiatric Association. Read the full article here: Aduhelm for Alzheimer’s: Questions Remain About Cost, Clinical Effectiveness – American Psychiatric Association News